Monitor for the company's compliance plan submission by June 29, 2026. A capital raise (equity or debt) is the most likely cure, which would be dilutive. Failure to regain compliance could lead to delisting, a severe liquidity event. The stock may face selling pressure as institutional holders reduce positions due to listing risk.
Price Chart
Executive Summary
Skye Bioscience received a Nasdaq delisting notice on May 13, 2026, for failing to meet the $10M minimum stockholders' equity requirement (reported equity: $9,011,804). The company has 45 days to submit a compliance plan, with a possible 180-day extension to cure. Failure to regain compliance could result in delisting from the Nasdaq Global Market, severely impacting liquidity and institutional ownership.
Key Facts
- Stockholders' equity was $9,011,804 as of March 31, 2026, below the $10,000,000 minimum required by Nasdaq Listing Rule 5450(b)(1)(A).
- Company has until June 29, 2026 to submit a compliance plan to Nasdaq.
- If plan is accepted, Nasdaq may grant an extension until November 9, 2026 to regain compliance.
- No immediate effect on trading; stock continues to trade under symbol SKYE.
- Company is evaluating alternatives but provides no assurance of regaining compliance.
Financial Impact
Stockholders' equity shortfall of approximately $988,196 against the $10M minimum requirement.
Risk Factors
- Delisting from Nasdaq if compliance plan is rejected or not executed within the extension period.
- Potential dilutive capital raise to boost equity above $10M.
- Loss of institutional investor base and liquidity upon delisting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-035535 |
| Document: 0001628280-26-035535-index-headers.html | 0001628280-26-035535 |
| Document: 0001628280-26-035535-index.html | 0001628280-26-035535 |
| Document: 0001628280-26-035535.txt | 0001628280-26-035535 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 6w ago | DEFA14A | $0.2809 $1.77 | ▲ +528.34% | ▲ +528.34% | $1.68 (+498.08%) |
Aug 14, 2026 7w ago | 8-K | $0.5015 $1.99 | ▲ +296.81% | ▲ +298.80% | $1.68 (+235.00%) |
Aug 14, 2026 7w ago | Press Release | $0.5015 $1.99 | ▼ −296.81% | ▼ −298.80% | $1.68 (−235.00%) |
May 15, 2026 20w ago | 8-K | $0.7780 $0.7184 | ▲ +7.66% | ▲ +9.24% | $1.68 (−115.94%) |
May 12, 2026 20w ago | Press Release | $0.8140 $0.7800 | ▲ +4.18% | ▲ +2.45% | $1.68 (−106.39%) |
Apr 29, 2026 22w ago | 3 | $0.8940 $0.8500 | ▼ −4.92% | ▼ −10.97% | $1.68 (+87.92%) |
Apr 16, 2026 24w ago | DEFA14A | $0.7500 $0.8200 | ▲ +9.33% | ▲ +3.52% | $1.68 (+124.00%) |
Apr 2, 2026 26w ago | Press Release | $0.6980 $0.8790 | ▲ +25.93% | ▲ +16.05% | $1.68 (+140.69%) |
Mar 10, 2026 29w ago | Press Release | $0.7210 $0.7260 | ▲ +0.69% | ▲ +0.17% | $1.68 (+133.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access